Stryker (SYK) reported $5.24 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.7%. EPS of $2.50 for the same period compares to $2.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $5.05 billion, representing a surprise of +3.74%. The company delivered an EPS surprise of +6.38%, with the consensus EPS estimate being $2.35.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Stryker (SYK) came out with quarterly earnings of $2.50 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.38%. A quarter ago, it was expected that this medical device maker would post earnings of $3.27 per share when it actually produced earnings of $3.46, delivering a surprise of 5.81%.Over the last four quarters, the compan ...

Exhibit 99.1 STRYKER REPORTS FIRST QUARTER 2024 OPERATING RESULTS Portage, Michigan - April 30, 2024 - Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results | | | | First Quarter Net Sales Growth Overview | | | | --- | --- | --- | --- | --- | --- | | | | Foreign Currency | Acquisitions / | | | | | Reported | Exchange | Constant Currency Divestitures | | Organic | | MedSurg and Neurotechnology | 11.5 % | (0.5)% | 12.0 % | 0.4 % | 11.6 % | | Orthopaedics and Spine ...

Wall Street analysts expect Stryker (SYK) to post quarterly earnings of $2.35 per share in its upcoming report, which indicates a year-over-year increase of 9.8%. Revenues are expected to be $5.06 billion, up 5.8% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give du ...

The global orthopedic space has seen significant transformative changes in recent times. Major players like Stryker (SYK) and Zimmer Biomet (ZBH) have rapidly adopted differentiated strategies to make up for the lost growth during the pandemic.Both these S&P 500 players, who have started their 2024 journey on an optimistic note, are due to report first-quarter 2024 results in the upcoming week. Accordingly, it’s time for investors to revisit their quarter’s takeaway and assess the overall growth potential t ...

Stryker Corporation (SYK) is scheduled to release first-quarter 2024 results on Apr 30, after market close. In the last reported quarter, the company delivered an earnings surprise of 5.81%.Q1 EstimatesThe Zacks Consensus Estimate for earnings is pegged at $2.35 per share, indicating an increase of 9.8% year over year.The consensus mark for revenues is pinned at $5.06 billion, implying growth of 5.8% from the prior-year quarter’s reported figure.Factors to NoteStryker's MedSurg and Neurotechnology segment w ...

The market expects Stryker (SYK) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Ap ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Stryker (SYK) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Stryker is one of 1062 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Ra ...

Stryker Corporation (SYK) recently announced that it has completed the acquisition of SERF SAS, a France-based joint replacement company from Menix.The acquisition of SERF SAS demonstrates Stryker’s commitment to orthopedic excellence and expands its worldwide range. Together with the SERF SAS team, Stryker aims to aid in advanced product innovation and customer satisfaction.Price PerformanceFor the past six months, SYK’s shares have rallied 23.0% compared with the industry’s rise of 10.0%. The S&P 500 incr ...

Stryker Corporation (SYK) is well poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. Meanwhile, an improvement in price also buoys optimism.Shares of this Zacks Rank #2 (Buy) company have risen 17.9% year to date compared with the industry’s 4.1% growth. The S&P 500 Index has increased 8.3% in the same time frame.Stryker, with a market capitalization of $135.6 billion, is one of the world’s largest medical device companies operating in the ...